Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Biogen Idec
(NQ:
BIIB
)
215.63
-0.71 (-0.33%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Mar 28, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
1,912,277
Open
217.36
Bid (Size)
212.05 (1)
Ask (Size)
216.17 (1)
Prev. Close
216.34
Today's Range
215.06 - 215.99
52wk Range
211.01 - 319.76
Shares Outstanding
144,000,000
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
Race To Treat Alzheimer's Disease Is Heating Up Despite Eli Lilly's Setback
Today 8:00 EDT
The FDA has delayed making a decision on Eli Lilly's donanemab, pending an advisory committee meeting.
Via
Investor's Business Daily
Exposures
Product Safety
Tuesday Talk: Big-Tech Under Attack
March 26, 2024
On Thursday the Justice Dept. filed an antitrust suit against Apple. The suit joins two others already filed against Google. How much this will affect the market in the long run is up for grabs.
Via
Talk Markets
Performance
YTD
-19.45%
-19.45%
1 Month
-3.71%
-3.71%
3 Month
-17.25%
-17.25%
6 Month
-16.37%
-16.37%
1 Year
-21.31%
-21.31%
More News
Read More
Wall Street’s Favorite Biotech Stocks? 3 Names That Could Make You Filthy Rich
March 25, 2024
Via
InvestorPlace
Forecasting The Future: 18 Analyst Projections For Biogen
March 25, 2024
Via
Benzinga
European Medicines Agency Delays Approval Decision For Biogen-Eisai Partnered Alzheimer's Drug Lecanemab
March 22, 2024
Via
Benzinga
A Closer Look at 21 Analyst Recommendations For Biogen
March 05, 2024
Via
Benzinga
Biogen Unusual Options Activity
February 29, 2024
Via
Benzinga
Biogen Inc. (BIIB) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings
March 21, 2024
From
Bronstein, Gewirtz & Grossman, LLC
Via
Business Wire
10 Health Care Stocks With Whale Alerts In Today's Session
March 20, 2024
Via
Benzinga
10 Health Care Stocks With Whale Alerts In Today's Session
March 19, 2024
Via
Benzinga
10 Big-Name Stocks Near 52-Week Lows: Are They A Buy?
March 16, 2024
Via
Talk Markets
Biogen Inc. (BIIB) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings
March 14, 2024
From
Bronstein, Gewirtz & Grossman, LLC
Via
Business Wire
Fed Rate Cut Expectations Rise After February Jobs Report: Friday's Stock Movers
March 08, 2024
Via
Benzinga
Topics
Economy
Exposures
Interest Rates
Are These 5 Undervalued Stocks Ready to Break Out?
March 08, 2024
Via
MarketBeat
Eli Lilly's Donanemab For Alzheimer's Hits FDA Speed Breaker, Biogen Stock Gains On Delayed Decision
March 08, 2024
Via
Benzinga
Exposures
Product Safety
FDA Delays Decision On Eli Lilly's Alzheimer Drug
March 08, 2024
Via
Investor's Business Daily
Exposures
Product Safety
Biogen's Spinraza For Muscle Movement Disorder Shows Improved Motor Function In Infants, Toddlers
March 06, 2024
Via
Benzinga
New Biomarker Data Add Further Evidence Supporting the Potential Benefit of SPINRAZA® (nusinersen) in Infants and Toddlers with Unmet Clinical Needs after Gene Therapy
March 06, 2024
From
Biogen Inc.
Via
GlobeNewswire
Biogen Highlights New Data at the International Conference on Alzheimer’s and Parkinson’s Diseases (AD/PD™) 2024 Annual Meeting
March 04, 2024
From
Biogen Inc.
Via
GlobeNewswire
Biotechs on the Rise: 3 Stocks to Buy for a Shot of Profits
March 04, 2024
Via
InvestorPlace
1 Wall Street Analyst Thinks Biogen Stock Is Going to $311. Is It a Buy Around $223?
March 02, 2024
Via
The Motley Fool
Top Stocks Not Named Nvidia You Need To Know About In 2024: Here's What Investors Think About Them (Wall Street Vs. Reddit)
February 29, 2024
Via
Benzinga
BIOGEN ALERT: Bragar Eagel & Squire, P.C. is Investigating Biogen Inc. on Behalf of Biogen Stockholders and Encourages Investors to Contact the Firm
February 24, 2024
From
Bragar Eagel & Squire
Via
GlobeNewswire
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Biogen Inc. (BIIB) on Behalf of Investors
February 23, 2024
From
Glancy Prongay & Murray LLP
Via
Business Wire
Biogen’s QALSODY® (tofersen), the First Therapy to Treat Rare, Genetic Form of ALS, Received Positive Opinion from CHMP
February 23, 2024
From
Biogen Inc.
Via
GlobeNewswire
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.